Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Momentum Builds To Move Comparative Effectiveness From Idea To Action

This article was originally published in The Tan Sheet

Executive Summary

Drug and medical device industry efforts to restrict comparative effectiveness research from morphing into outright cost comparisons might be a losing battle, according to speakers at an industry conference

You may also be interested in...



Comparative Effectiveness Language Clarified In Compromise Stimulus Bill

Congress took steps in its final version of the economic stimulus package to alleviate concerns that the comparative effectiveness research provisions will lead to the government making cost-based comparisons or making coverage and reimbursement decisions based on the research

Comparative Effectiveness Language Clarified In Compromise Stimulus Bill

Congress took steps in its final version of the economic stimulus package to alleviate concerns that the comparative effectiveness research provisions will lead to the government making cost-based comparisons or making coverage and reimbursement decisions based on the research

Comparative Effectiveness Language Clarified In Compromise Stimulus Bill

Congress took steps in its final version of the economic stimulus package to alleviate concerns that the comparative effectiveness research provisions will lead to the government making cost-based comparisons or making coverage and reimbursement decisions based on the research

Topics

UsernamePublicRestriction

Register

ID1132298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel